Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CCBP2 encodes a beta chemokine receptor, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Additionally we are shipping CCBP2 Proteins (4) and CCBP2 Kits (3) and many more products for this protein.
Showing 10 out of 93 products:
Human Polyclonal CCBP2 Primary Antibody for IHC (p), ELISA - ABIN4369828
Soler, Humphreys, Spinola, Campbell: CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. in Blood 2003
Show all 3 Pubmed References
Human Monoclonal CCBP2 Primary Antibody for CyTOF, FACS - ABIN4899116
Martinez de la Torre, Buracchi, Borroni, Dupor, Bonecchi, Nebuloni, Pasqualini, Doni, Lauri, Agostinis, Bulla, Cook, Haribabu, Meroni, Rukavina, Vago, Tedesco, Vecchi, Lira, Locati, Mantovani: Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 3 Pubmed References
Data show the structural motifs in the atypical chemokine receptor 2 (ACKR2) are responsible for ligand binding, and suggest ACKR2-derived N-terminal peptides as being of potential therapeutic significance.
engagement of the ACR (show ACR Antibodies) D6 by its ligands activates a beta (show SUCLA2 Antibodies)-arrestin1 (show ARRB1 Antibodies)-dependent, G protein-independent signaling pathway that results in the phosphorylation of the actin-binding protein (show KPTN Antibodies) cofilin (show CFL1 Antibodies) through the Rac1-PAK1 (show PAK1 Antibodies)-LIMK1 (show LIMK1 Antibodies) cascade.
co-expression of DARC (show DARC Antibodies), D6, and CCX-CKR (show CCRL1 Antibodies) significantly associated with higher survival in gastric cancer
CCL2 binding to primary adult human astrocytes is CCR2-independent and is likely to be mediated via the D6 decoy.
D6 is expressed in AMs (show MAT1A Antibodies) from patients with COPD (show ARCN1 Antibodies), and its expression correlates with the degree of functional impairment and markers of immune activation.
Chemokine (show CCL1 Antibodies) decoy receptor D6 limits CC-chemokine (show CCL1 Antibodies)-dependent pathogenic inflammation and is required for adequate cardiac remodeling after myocardial infarction.
DARC (show DARC Antibodies) and D6, the most studied members of this group of molecules, are reviewed.
CCR10 (show CCR10 Antibodies) is unlikely to be necessary for cutaneous homing of TH cells in the models studied here. CCR10 (show CCR10 Antibodies) may instead play a role in the movement of specialized "effector" cutaneous TH cells to and/or within epidermal microenvironments.
CCR10 and its mucosal epithelial ligand CCL28 have roles in the migration of circulating IgA plasmablasts
a comprehensive model of CCL19 (show CCL19 Antibodies) and CCL21 (show CCL21 Antibodies) transport and gradient formation in the lymph nodes (LNs) was built; predicts that ACKR4 in LNs prevents CCL19 (show CCL19 Antibodies)/CCL21 (show CCL21 Antibodies) accumulation in efferent lymph, but does not control intranodal gradients; instead, it attributes the disrupted interfollicular CCL21 (show CCL21 Antibodies) gradients observed in Ackr4-deficient LNs to ACKR4 loss upstream
study found that the inflammatory chemokine (show CCL1 Antibodies) CCL5 (show CCL5 Antibodies) is mostly retained (75%) during the resolution of zymosan A peritonitis in mice; CCL5 (show CCL5 Antibodies) exerts a novel proresolving role on macrophages when acting in concert with apoptotic PMN (show TBCE Antibodies)-expressed D6.
ACKR4 on stromal cells aids the egress of antigen presenting cells from mouse skin, and, during inflammation, facilitates CCR7 (show CCR7 Antibodies)-dependent cell trafficking by scavenging CCL19 (show CCL19 Antibodies).
The data shows a novel function for the chemokine receptor CCX-CKR (show CCRL1 Antibodies) as a regulator of TGF-beta1 (show TGFB1 Antibodies) expression and epithelial-mesenchymal transition in breast cancer cells.
CCRL1 (show CCRL1 Antibodies) is expressed in key thymic microenvironments but is dispensable for T lymphopoiesis at steady state in adult mice.
Further examination revealed that proximity of pro-lymphangiogenic macrophages to developing lymphatic vessel surfaces is increased in ACKR2-deficient mice and reduced in CCR2-deficient mice.
stepwise acquisition of chemokine (C-C motif) receptor-like 1 (CCRL1 (show CCRL1 Antibodies)) is a late determinant of cortical thymic epithelial cell differentiation
some cells, including plasmacytoid dendritic cells, can express both CCR2 (show CCR2 Antibodies) and ACKR2; that Ly6C(high) monocytes have particularly strong CCL2 (show CCL2 Antibodies)-scavenging potential in vitro and in vivo; and that CCR2 (show CCR2 Antibodies) is a much more effective CCL2 (show CCL2 Antibodies) scavenger than ACKR2.
found that lymph node fringes indeed contained physiological gradients of the chemokine (show CCL1 Antibodies) CCL21 (show CCL21 Antibodies), which depended on the expression of CCRL1 (show CCRL1 Antibodies), the atypical receptor for the CCR7 (show CCR7 Antibodies) ligands CCL19 (show CCL19 Antibodies) and CCL21 (show CCL21 Antibodies)
CCX-CKR (show CCRL1 Antibodies) deletion increases incidence of a spontaneous Sjogren's syndrome-like pathology, suggestive of a defect in self-tolerance. CCX-CKR (show CCRL1 Antibodies)(-/-) mice have fewer thymic epithelial cells per thymocyte, with defects in thymocyte distribution & frequency.
This gene encodes a beta chemokine receptor, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Chemokines and their receptor-mediated signal transduction are critical for the recruitment of effector immune cells to the inflammation site. This gene is expressed in a range of tissues and hemopoietic cells. The expression of this receptor in lymphatic endothelial cells and overexpression in vascular tumors suggested its function in chemokine-driven recirculation of leukocytes and possible chemokine effects on the development and growth of vascular tumors. This receptor appears to bind the majority of beta-chemokine family members\; however, its specific function remains unknown. This gene is mapped to chromosome 3p21.3, a region that includes a cluster of chemokine receptor genes.
C-C chemokine receptor D6
, CC-chemokine-binding receptor JAB61
, chemokine (C-C motif) receptor 9
, chemokine (C-C) receptor 9
, chemokine binding protein 2
, chemokine receptor CCR-10
, chemokine receptor CCR-9
, chemokine receptor D6
, chemokine-binding protein 2
, chemokine-binding protein D6
, CCR10-related receptor
, C-C CKR-11
, C-C chemokine receptor type 11
, CC chemokine receptor-like 1
, CCX CKR
, chemokine (C-C motif) receptor-like 1
, chemokine (C-C) receptor-like 1
, chemokine receptor CCR11
, D6 beta-chemokine receptor